HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Management of Immunotherapy-Related Toxicities, Version 1.2019.

Abstract
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.
AuthorsJohn A Thompson, Bryan J Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S Ernstoff, Matthew Frigault, Brianna Hoffner, Christopher J Hoimes, Mario Lacouture, Frederick Locke, Matthew Lunning, Nisha A Mohindra, Jarushka Naidoo, Anthony J Olszanski, Olalekan Oluwole, Sandip P Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A Sosman, Momen Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L Scavone
JournalJournal of the National Comprehensive Cancer Network : JNCCN (J Natl Compr Canc Netw) Vol. 17 Issue 3 Pg. 255-289 (03 01 2019) ISSN: 1540-1413 [Electronic] United States
PMID30865922 (Publication Type: Journal Article, Practice Guideline)
Chemical References
  • Antineoplastic Agents, Immunological
Topics
  • Antineoplastic Agents, Immunological (adverse effects, therapeutic use)
  • Disease Management
  • Drug-Related Side Effects and Adverse Reactions (diagnosis, etiology, therapy)
  • Humans
  • Molecular Targeted Therapy (adverse effects, methods)
  • Neoplasms (complications, drug therapy, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: